Labcorp Seen Steady Ahead of Q2 Report as Diagnostics Growth Offsets Central Lab Decline

Labcorp is scheduled to report second-quarter 2026 results on July 30, 2026, with the market looking for continued strength in its Diagnostics Laboratories segment to offset ongoing softness in central lab (drug-development-related) revenue, a dynamic that has shaped the company's narrative in recent quarters. Consensus estimates going into the print call for revenue of roughly $3.72 billion, up about 5.4% year over year, and adjusted EPS of around $4.79, an improvement of roughly 10% from the year-ago period, according to analyst estimates compiled ahead of the release.

The diagnostics segment's specialty testing portfolio, spanning oncology, women's health, neurology, and autoimmune disease, has been a consistent growth driver and is expected to remain one heading into the print. Meanwhile, recent analyst upgrades and attention around the company's ColoSense colorectal cancer screening test have contributed to a more constructive narrative around the stock even before the formal results land.

Because the underlying quarterly figures have not yet been confirmed as of this writing, the specific magnitude of any diagnostics-versus-central-lab offset for Q2 2026 remains an open question rather than a settled fact. Investors could watch the July 30 release for whether Labcorp's diagnostics momentum was strong enough to fully offset central lab softness, and whether management's guidance validates the more optimistic analyst tone that has built up ahead of the print.

Related Stocks

• LH